|
|
|
| PYRAZINAMID FARMAPOL |
|
COMPOSITION:
1 tablet contains pirazyncarboxyamide 0,5g (potato starch, gelatin, talc).
PROPERTIES AND ACTION:
Chemomedicine, with bactericidal effect on bacilli in the acid medium. It belongs to the strongest bacteriocidal medicines among the anti-bacillus medicaments. It has a sterilising effect on the bacilli free-growing inside of macrophages, and Mycobacterium bovis. It is easily and entirely absorbed from the digestive system, after two hours obtaining the maximal concentration in the blood. It's effective for 10-24 hours. Pyrazinamid easily penetrates into the cerebrospinal fluid. In the liver, it is metabolised into the active pirazine acid. About 70% of the medicine is excreted with urine within 24 hours as metabolites and about 4% in an unchanged state.
INDICATIONS:
Currently Pyrazinamid is used in the first phase of the treatment (first 2 months) together with rifampycin, hydrazide and streptomycin. It is a basic medicine in a short-term 6-month treatment. It's effective in the treatment of TB meningitis.
CONTRAINDICATIONS:
Severe kidney and liver diseases; gout; porphyria; should not be used in children and in women during pregnancy and lactation.
WARNINGS:
The toxicity of the medicine is considerable even in the medical doses and depends mainly on the size of the dose and therefore precautions should be taken by doctors prescribing it. A dose exceeding 1,5g per 24 hours may lead to liver damage and icterus. A dose of 3,0g per 24 hours may cause severe yellow liver atrophy. Occasionally, a clinic picture of gout and increase in the level of uric acid may occur but in majority of cases the symptoms do not make it necessary to discontinue the treatment. Generally, the following precautions should be taken:
- children may administer pyrazinamid only in hospital treatment,
- in case of adults the treatment should begin in hospital; further treatment must be conducted under a supervision of a phthisiologist,
- a systematic comparative check of the liver activity should be carried out every 10-14 days (determination of the glutamine-oxalate-acetic transaminase activity, determination of the level of bilirubin in blood serum and the level of urobilinogen in urine,
- pyrazinamid must not be used in patients suffering from tuberculosis who have had liver disease, in alcoholics and in people with positive results of liver tests before the beginning of a treatment. Simultaneous use of insulin or anti-diabetic medicines and pyrazinamid in patients suffering from diabetes increases the difficulty in controlling the concentration of glucose in the blood.
DOSAGE:
As determined by the doctor; the medicine should only be used in hospital service. It is used together with other anti-bacillus medicines. Orally 20-30 mg/kg of body weight per 24 hours, on the average 1,5g at a time. The dose should be reduced if the patient suffers from severe kidney disease.
NON-DESIRABLE ACTION:
- it may cause digestive system disorders (nausea, vomit, lack of hunger);
- allergic reactions (rash, photophobia);
- bleeding, elevated body temperature, difficulties in urinating, severe attacks of gout;
- the risk of damaging the flesh of the liver is commensurate with the dose and length of the treatment. Pyrazinamid used in a dose not exceeding 30mg/kg of body weight and together with hydrazide and rifampycin for the first two months of the treatment does not increase substantially the hepatoxicity of the set.
VALIDITY PERIOD:
3 years from the date of production.
Do not use if outdated.
STORAGE:
Keep out of reach of children. Protect from direct light and moisture.
CONTAINER:
250 tablets.
Licence nr R/2635.
|
Before using the drug, read the information leaflet which contains indications, contraindications, data concerning adverse effects and dosaging as well as information relating to the use of the medical product, or consult your physician or pharmacist.
|
|
|
